| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 11033595 | Cancer Treatment Reviews | 2018 | 30 Pages |
Abstract
Management of non metastatic castrate resistant prostate cancer is challenging for clinicians due to the heterogeneity of the disease and to the scarce clinical data available in this setting. Recent results obtained with the new generation hormone therapies (NGHT) apalutamide and enzalutamide bring a new perspective for the treatment strategy. The authors present here a systematic review of the treatment options.
Keywords
ADTmetastatic CRPCPSALHRHPSADTMFSNon-metastaticmCRPCCRPCPFsprogression-free survivaloverall survivalandrogen deprivation therapyRadiotherapyRadical prostatectomyPSA doubling timeProstate cancerCastration-resistant prostate canceradverse eventCastration-resistantluteinizing hormone-releasing hormoneprostate-specific antigen
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Yohann Loriot, Stéphane Supiot, Jean-Baptiste Beauval, Friederike Schlürmann, Gilles Pasticier, Paul Sargos, Philippe Barthélémy, Géraldine Pignot, Denis Maillet, Sébastien Vincendeau, Emmanuel Gross, Guillaume Ploussard, Marc-Olivier Timsit,